Publication Date: March 2015
Top Reasons to Buy This HEOR Teams Report
Balance short-term approval needs with long-term market access and payer needs: HEOR Teams face challenges in communicating the importance of health economics and outcomes research prior to launch, and resource prioritization is an obstacle. Botched launches in major markets can ripple through the entire market access budget. Building World-Class HEOR Teams examines how to structure and resource Health Economics & Outcomes Research groups effectively. Dedicated HEOR Teams provide the advantage of coordinating both prospective and retrospective health economics and outcomes research activities. The study also includes case studies of real-company HEOR organizational structures; these examples also show how to most effectively manage vendors for HEOR activities. Metrics include total HEOR budgets, sources of funding for HEOR activities, and funding allocation between compounds in development and marketed brands.
Use the right HEOR studies to build understanding of what is driving patient needs — and to address payer requirements: Getting an early start on developing the health economics plan for a product is crucial in meeting payer needs. Identifying comparators and understanding the competitive landscape at launch can be difficult in early phases — but groups are still able to conduct research that lays the groundwork for a product’s future success on the market. Once launch approaches and health economics and outcomes research involvement reaches its peak, companies should know how many studies are required to support a product effectively, as well as the potential budgetary pressures that come with addressing payer concerns. This report guides companies in making critical decisions and planning surrounding HEOR studies and their costs. Benchmarks include how many health economics studies are conducted and their cost and duration.
Plan to increase health outcomes liaison (HOL) headcounts as payers demand more detailed information: The study examines HEOR team staffing as well as the activities and strategies that impact their operations. Research highlights staffing numbers across central global groups and affiliate-level health economics and outcomes research teams as well as compensation structure for individual team positions. Interviewed executives explain the rising need, and increased role, for health outcomes liaisons (HOLs) to discuss pharmacoeconomic data with payers as part of a compelling value story. Other data demonstrate the core activities driving strategy across HEOR groups as well as perceived impact of health economics and outcomes data for specific payers’ formulary decisions. Altogether, the information in this report helps companies build skilled, focused HEOR Teams capable of adjusting to payer needs throughout the product lifecycle.
Excerpt from Building World Class HEOR Teams
When it comes to meeting payer needs from a health economics perspective,
pharmaceutical companies are under increasing pressure to provide a full value story to payers that answers outcomes, pharmacoeconomic and even budgetary questions. Stakeholders, including payers, physicians, and even patients in many markets, now expect to see a pharmacoeconomic case for the use of a new product. These demands place a growing burden on the health economics groups responsible for generating these data. They also present a challenge in communicating these findings to payers successfully.
This report serves as a guide for structuring health economics operations at the global and country levels. Its data and best practices will help teams on the ground focus on working with directly with payers while being effectively supported by global groups.